{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 4
  },
  "completeness_stats": {
    "existing_evidence": 2,
    "new_evidence_found": 4,
    "total_evidence": 6
  },
  "verified_evidence": [
    {
      "id": 2,
      "quote": "Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit",
      "supports_claim": true,
      "explanation": "A very similar quote appears on page 2: 'Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit'. The wording and numbers match the quote to verify, with only minor formatting differences.. The quote directly identifies Fluarix IIV4 as one of the quadrivalent standard-dose vaccines used in the trial, with specific enrollment and follow-up numbers. The broader context of the document confirms that Flublok (RIV4, recombinant quadrivalent) was evaluated in the same trial, and the quote shows that Fluarix (quadrivalent standard-dose) was a comparator. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "A very similar quote appears on page 2: 'Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit'. The wording and numbers match the quote to verify, with only minor formatting differences.",
      "support_explanation": "The quote directly identifies Fluarix IIV4 as one of the quadrivalent standard-dose vaccines used in the trial, with specific enrollment and follow-up numbers. The broader context of the document confirms that Flublok (RIV4, recombinant quadrivalent) was evaluated in the same trial, and the quote shows that Fluarix (quadrivalent standard-dose) was a comparator. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote identifies Fluarix IIV4 as one of the quadrivalent standard-dose vaccines used in the trial, supporting that Flublok (RIV4) was evaluated against Fluarix (IIV4)."
    },
    {
      "id": 4,
      "quote": "n=318 (*139) IIV4-ccIIV4 n=106 (*51) IIV4-RIV4 n=104 (*44) IIV4-IIV4 n=103 (*41)",
      "supports_claim": true,
      "explanation": "The quote 'n=318 (*139) IIV4-ccIIV4 n=106 (*51) IIV4-RIV4 n=104 (*44) IIV4-IIV4 n=103 (*41)' appears on page 2 of the document, almost verbatim. The context is a CONSORT diagram listing the randomization arms for the study, including IIV4-RIV4, IIV4-IIV4, and IIV4-ccIIV4. The abbreviations are explained in the same section, with IIV4 defined as 'inactivated influenza vaccine (Fluzone or Fluarix\u00ae Quadrivalent)' and RIV4 as 'recombinant hemagglutinin influenza vaccine (Flublok\u00ae Quadrivalent)'.. The quote directly lists the randomization arms of the pivotal trial, including IIV4-RIV4, which means participants received IIV4 (such as Fluarix) in one year and RIV4 (Flublok) in another. The document explicitly defines IIV4 as including Fluarix and RIV4 as Flublok. This demonstrates that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine), directly supporting the claim.",
      "presence_explanation": "The quote 'n=318 (*139) IIV4-ccIIV4 n=106 (*51) IIV4-RIV4 n=104 (*44) IIV4-IIV4 n=103 (*41)' appears on page 2 of the document, almost verbatim. The context is a CONSORT diagram listing the randomization arms for the study, including IIV4-RIV4, IIV4-IIV4, and IIV4-ccIIV4. The abbreviations are explained in the same section, with IIV4 defined as 'inactivated influenza vaccine (Fluzone or Fluarix\u00ae Quadrivalent)' and RIV4 as 'recombinant hemagglutinin influenza vaccine (Flublok\u00ae Quadrivalent)'.",
      "support_explanation": "The quote directly lists the randomization arms of the pivotal trial, including IIV4-RIV4, which means participants received IIV4 (such as Fluarix) in one year and RIV4 (Flublok) in another. The document explicitly defines IIV4 as including Fluarix and RIV4 as Flublok. This demonstrates that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine), directly supporting the claim.",
      "original_relevance": "This quote lists the randomization arms, including IIV4-RIV4, which means participants received IIV4 (such as Fluarix) in one year and RIV4 (Flublok) in another, demonstrating a direct comparison between these vaccines."
    }
  ],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quad rival ent in activated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were collected from healthcare personnel (18-64 years) in 2018 19 (N = 723) and 2019 20 (N = 684) influenza seasons.",
      "relevance_explanation": "This quote describes the randomized trial design, explicitly stating that quadrivalent recombinant (RIV4, i.e., Flublok) and quadrivalent egg-based (IIV4, which includes Fluarix) vaccines were evaluated, supporting the claim that Flublok was evaluated against a standard-dose quadrivalent vaccine.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote lists the vaccine allocation, showing that Fluarix (a standard-dose quadrivalent vaccine) and RIV4 (Flublok) were both used in the pivotal trial, directly supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "ccIIV4: Cell culture based IIV4 (Flu cel vax Quad rival ent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quad rival ent by SanofiPasteur, RIV4).",
      "relevance_explanation": "This quote clarifies that RIV4 refers to Flublok Quadrivalent, confirming that Flublok was one of the vaccines evaluated in the trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_4",
      "quote": "During Year 1, HCP were stratified by two age groups (18\u221244 years and 45\u221264 years) and randomized at 4 4 2 2",
      "relevance_explanation": "This quote indicates that participants were randomized to different vaccine groups, supporting that a head-to-head comparison was performed in the pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}